Cancer drug combo trial halted early – what we learned
NCT ID NCT05578092
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 31 times
Summary
This early-stage trial tested a new drug, MRTX0902, alone or with another drug (adagrasib) in 64 people with advanced solid tumors that have specific KRAS gene mutations. The goal was to check safety and how the body processes the drug. The study was stopped early, but the information gathered helps researchers understand dosing and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 001-101
Nashville, Tennessee, 37203, United States
-
Local Institution - 001-102
Nashville, Tennessee, 37203, United States
-
Local Institution - 001-103
Baltimore, Maryland, 21287, United States
-
Local Institution - 001-104
Fairfax, Virginia, 22031, United States
-
Local Institution - 001-105
Seattle, Washington, 98109, United States
-
Local Institution - 001-106
Cincinnati, Ohio, 45219-2364, United States
-
Local Institution - 001-107
Houston, Texas, 77030, United States
-
Local Institution - 001-108
New Haven, Connecticut, 06520, United States
-
Local Institution - 001-109
Portland, Oregon, 97239-3011, United States
-
Local Institution - 001-110
Rochester, Minnesota, 55905-0001, United States
-
Local Institution - 001-111
Orlando, Florida, 32827-7400, United States
-
Local Institution - 001-112
Dallas, Texas, 75246-2003, United States
-
Local Institution - 001-114
Rio Piedras, 00935, Puerto Rico
-
Local Institution - 001-115
Hackensack, New Jersey, 07601-2191, United States
-
Local Institution - 001-116
Pittsburgh, Pennsylvania, 15232, United States
-
Local Institution - 001-119
Newark, Delaware, 19713-2055, United States
-
Local Institution - 001-122
Fort Worth, Texas, 76104-2154, United States
-
Local Institution - 001-123
Tyler, Texas, 75708-3154, United States
Conditions
Explore the condition pages connected to this study.